Latest News for RDY
Dr. Reddy's Laboratories NYSE: RDY said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety concerns.
Dr. Reddy's Laboratories Limited (RDY) Discusses Manufacturing Issue and Process Review for Semaglutide Transcript
Torrent Pharmaceuticals said on Thursday it was voluntarily recalling select batches of its Semalix semaglutide injection disposable pens after a product recall notification from its manufacturer Dr. Reddy's Laboratories.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanDepositaryReceipts--Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F.
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bosulif--Dr. Reddy's Laboratories Ltd. announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif® in the United States.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RDY.
U.S. House Trading
No House trades found for RDY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.